PTGX stock: buy or sell?

PTGX stock price: $13.81 0.22% At close on September 20th, 2019

Updated on:
September 20th, 2019


Protagonist Therapeutics shares stayed steady 0.22% to $13.81 today. On Sep/18 PTGX collapsed a scary -5.27%.

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based chemical entities to address various unmet medical needs.

Should I buy PTGX stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. There are thousands of trading strategies for you to choose, but at we prefer those that are simple but successful.

Currently, Protagonist Therapeutics stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean PTGX will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Protagonist Therapeutics stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At, we detected 2 ratings published for PTGX stock in the last 30 days.

Is PTGX a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-7-8HC Wainwrightn/aBuy
2019-2-22BMO Capital Marketsn/aOutperform

PTGX stock analysis

Daily outlook

Shares of Protagonist Therapeutics ended today at $13.81 and stayed constant a slightly fine 0.22%.

Shares of Protagonist Therapeutics closed today at $13.81 and stayed steady a slightly fine 0.22%. On Aug/13 PTGX price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock.

PTGX stock chart (daily)

Weekly outlook

Protagonist Therapeutics plummed a spooky -6.82% this week. Early September PTGX climbed an amazing 16.26% in just one week.

Since mid August when PTGX stock price broke up the SMA40w line, it gained $4.39 (46.60%). Since SMA20d and SMA40w crossed up early April, PTGX price climbed $0.85 per share (6.56%).

PTGX stock chart (weekly)

PTGX stock price history

PTGX IPO was on August 11th, 2016 at $12.00 per share1. Since then, PTGX stock surged a 15.10%, with a yearly average of 5.00%. If you had invested right after PTGX's IPO a $1,000 in PTGX stock in 2016, it would worth $151.00 today.

1: Adjusted price after possible price splits or reverse-splits.

PTGX stock historical price chart

PTGX stock reached 52-week highs on Sep/10 at $16.67, and all-time highs 2016-12-06 with a price of 26.36.

PTGX stock price target is $20.00

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we found 2 price predictions for Protagonist Therapeutics stock:
PTGX stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-7-8HC WainwrightInitiatesn/a$23.00-
2019-2-22BMO Capital MarketsInitiatesn/a$17.00-
(in average)$0.00$20.000.0%
Moving in a range from $23.00 and $17.00, the price prediction for PTGX stock is $20.00. In average, analysts' outlook on PTGX price target is stable from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On March, Protagonist reported its latest financial data, posting an amazing climb for the Earnings per Share (EPS) ratio. Experts expected $-0.42 per share, but Protagonist posted $-0.57.
PTGX earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, Protagonist Therapeutics annual turnover climbed an exceptional 54.14% to $30.93 million dollars from $20.06 marked in 2017. Aligned with this, its income margin (compared to sales) boosted to -125.87%, that is $-38.92 million.

PTGX annual Sales and Income evolution
2017$20 M-$-36.96 M-184.2%-
2018$31 M54.14%$-38.92 M-125.9%5.32%

Quarterly financial results

Protagonist Therapeutics posted $2.35 M in sales for 2018-Q4, a -61.53% decline compared to previous quarter. Reported quarter earnings marked $-13.87 M with a profit margin of -589.25%. Profit margin plummed a -446.45% compared to previous quarter when profit margin was -142.80%. When comparing sales to same quarter last year, Protagonist sales marked a spooky correction and collapsed a -79.14%. Looking back to recent quarterly results, Protagonist posted 2 negative quarters in a row.
PTGX quarterly Sales and Income evolution
2017-Q3$9 M-$-4.83 M-54.9%-
2017-Q4$11 M28.48%$-3.05 M-27.1%-36.75%
2018-Q1$11 M-4.44%$-7.66 M-71.1%151.02%
2018-Q2$12 M8.28%$-8.66 M-74.2%13.08%
2018-Q3$6 M-47.60%$-8.74 M-142.8%0.83%
2018-Q4$2 M-61.53%$-13.87 M-589.2%58.73%

Protagonist ownership

When you are planning to invest in a company, it's worth to have a look its ownership structure.

Protagonist shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 5.26% of all shares.

Bearish positions for PTGX stock account 0.00%, no big difference from last month.

For a better context understanding, the next table shows ownership data compared to other related stocks:

Market cap$323.2 M$259.4 M$260.8 M
Total shares23.4 M120.7 M49.4 M
Float shares16.3 M102.9 M45.3 M
  - Institutional holdings (%)90.4%95.2%72.8%
  - Insider holdings (%)5.3%2.5%0.2%
Shares in short selling0.0%0.0%0.0%

PTGX summary

Friday, September 20th, 2019
Day range$13.70 - $13.92
Previous close$13.78
Session gain0.22%
Average true range$0.99
50d mov avg$12.41
100d mov avg$11.85
200d mov avg$10.40
Daily pattern
Weekly pattern

Protagonist performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. In the following table, we compare Protagonist Therapeutics performance to PDL BioPharma and Pieris Pharmaceuticals:
PTGXProtagonist Thera...14.89%0.51%60.39%
PDLIPDL BioPharma-28.09%-40.11%-11.52%
PIRSPieris Pharmaceut...15.79%69.23%-1.31%

Protagonist competitors

Creating a list of competitors for Protagonist it's not an easy task. We selected 2 public companies that are related to and can be considered as competitors of Protagonist: